Drug & Cancer & Variant
Result
Search content: Gene = AKT3
There are 2 entries with your keyword(s).
Gene Variant Type Tumor Drug Drug level Reference More
AKT3 AKT3-. FUS Breast Cancer ATP competitive AKT inhibitors V 1
Evidence region

CGI

Patient Criteria

-

Note

Furthermore, we have identified a recurrent MAGI3-AKT3 fusion enriched in triple-negative breast cancer lacking estrogen and progesterone receptors and ERBB2 expression. The Magi3-Akt3 fusion leads to constitutive activation of Akt kinase, which is abolished by treatment with an ATP-competitive Akt small-molecule inhibitor.

Gene name

AKT3

Full name

AKT serine/threonine kinase 3

Gene type

protein-coding

Function

The protein encoded by this gene is a member of the AKT, also called PKB, serine/threonine protein kinase family. AKT kinases are known to be regulators of cell signaling in response to insulin and growth factors. They are involved in a wide variety of biological processes including cell proliferation, differentiation, apoptosis, tumorigenesis, as well as glycogen synthesis and glucose uptake. This kinase has been shown to be stimulated by platelet-derived growth factor (PDGF), insulin, and insulin-like growth factor 1 (IGF1). Alternatively splice transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Jul 2008]

Sorry, there is no related drug information.

AKT3 E17K MUT Melanoma Vemurafenib RIII 1
Evidence region

CIVIC

Patient Criteria

-

Note

An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express AKT3 E17K were significantly more resistant to BRAF inhibition via vemurafenib than cells transduced with empty vectors (40% vs 20% survival, p = .0033).

Gene name

AKT3

Full name

AKT serine/threonine kinase 3

Gene type

protein-coding

Function

The protein encoded by this gene is a member of the AKT, also called PKB, serine/threonine protein kinase family. AKT kinases are known to be regulators of cell signaling in response to insulin and growth factors. They are involved in a wide variety of biological processes including cell proliferation, differentiation, apoptosis, tumorigenesis, as well as glycogen synthesis and glucose uptake. This kinase has been shown to be stimulated by platelet-derived growth factor (PDGF), insulin, and insulin-like growth factor 1 (IGF1). Alternatively splice transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Jul 2008]

Drug name

Vemurafenib

DrugBank ID

DB08881

Synonyms

Vémurafénib
Vemurafenib
Vemurafenibum

Brand

Zelboraf

Description

Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF.[A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]

Target gene
GeneFunction
BRAFinhibitor
Showing 1 to 2 of 2 entries, entries per page